Combined pyrimethamine-quinine therapy for chloroquine-resistant P. falciparum infections.
D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced; D000743:Anemia, Hemolytic / Q000139:chemically induced; D002738:Chloroquine / Q000008:administration & dosage; D019411:Clinical Laboratory Techniques; D004352:Drug Resistance, Microbial; D005334:Fever / Q000209:etiology; D006801:Humans; D007501:Iron / Q000378:metabolism; D008288:Malaria / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010963:Plasmodium falciparum; D010966:Plasmodium vivax; D011739:Pyrimethamine / Q000008:administration & dosage* / Q000009:adverse effects; D011803:Quinine / Q000008:administration & dosage* / Q000009:adverse effects; D012612:Scrub Typhus / Q000188:drug therapy; D013411:Sulfadiazine / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced; D014744:Vietnam
D013411:Sulfadiazine; D002738:Chloroquine; D011803:Quinine; D007501:Iron; D011739:Pyrimethamine